JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

྾

Home
Compounds
ALA265320

10-[2-[1-(Methoxymethyl)-4-[1-(methoxymethyl)-4-[1-(methoxymethyl)-4-butyramidopyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]ethoxy]-20(R,S)-camptothecin

ID: ALA265320

Chembl Id: CHEMBL265320

PubChem CID: 44311598

Max Phase: Preclinical

Molecular Formula: C47H51N9O12

Molecular Weight: 933.98

Molecule Type: Small molecule

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CCCC(=O)Nc1ccc(C(=O)Nc2cc(C(=O)Nc3cc(C(=O)NCCOc4ccc5nc6c(cc5c4)Cn4c-6cc5c(c4=O)COC(=O)C5(O)CC)n(COC)c3)n(COC)c2)n1COC

Standard InChI: InChI=1S/C47H51N9O12/c1-6-8-40(57)52-39-12-11-35(56(39)26-66-5)43(59)49-30-18-38(54(22-30)25-65-4)44(60)50-29-17-37(53(21-29)24-64-3)42(58)48-13-14-67-31-9-10-34-27(16-31)15-28-20-55-36(41(28)51-34)19-33-32(45(55)61)23-68-46(62)47(33,63)7-2/h9-12,15-19,21-22,63H,6-8,13-14,20,23-26H2,1-5H3,(H,48,58)(H,49,59)(H,50,60)(H,52,57)

Standard InChI Key: JYRIRRVYCISNBE-UHFFFAOYSA-N

Alternative Forms

Parent:

ALA265320
5-(butanoylamino)-N-[5-[[5-[2-[(19-ethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl)oxy]ethylcarbamoyl]-1-(methoxymethyl)pyrrol-3-yl]carbamoyl]-1-(methoxymethyl)pyrrol-3-yl]

Associated Targets(Human)

SK-OV-3 (52876 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SK-VLB (48 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HT-29 (80576 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

KB (17409 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Molecule Features

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Small molecule	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Drug Indications

MESH ID	MESH Heading	EFO IDs	EFO Terms	Max Phase for Indication	References

Mechanisms of Action

Mechanism of Action	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	References

Calculated Properties

Molecular Weight: 933.98	Molecular Weight (Monoisotopic): 933.3657	AlogP: 4.35	#Rotatable Bonds: 19
Polar Surface Area: 249.53	Molecular Species: NEUTRAL	HBA: 17	HBD: 5
#RO5 Violations: 2	HBA (Lipinski): 21	HBD (Lipinski): 5	#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.71	CX Basic pKa: 3.15	CX LogP: 2.45	CX LogD: 2.45
Aromatic Rings: 6	Heavy Atoms: 68	QED Weighted: 0.06	Np Likeness Score: -0.13

References

1. Zhao R, al-Said NH, Sternbach DL, Lown JW.. (1997) Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro., 40 (2): [PMID:9003520] [10.1021/jm9605804]

Source

Source(1):

Scientific Literature